Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases
Novabio Therapeutics and OBiO Tech, Inc. (SHA: 688238) have expanded their strategic collaboration to accelerate...
OBiO Technology
Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems
Itcure, a gene editing specialist based in Suzhou, has entered into a partnership with compatriot...
OBiO Technology Partners with Hanxin Biotechnology to Advance LNP Delivery System
China-based gene therapy Contract Research Organization (CRO) OBiO Technology (Shanghai) Co., Ltd (SHA: 688238) has...
OBiO Technology Partners with Shenzhen Innovation Immunotechnology for TCR-T Cell Therapy Development
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading Contract Research Organization (CRO) specializing in...
OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in...
ACROBiosystems Partners with OBiO Technology to Advance Cell and Gene Therapy
ACROBiosystems Group (SHE: 301080) has announced a partnership with China-based gene therapy specialist OBiO Technology...
OBiO Technology and ImmVira Partner on Oncolytic Virus Project for BLA Filing and Commercialization
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading gene therapy specialist based in China,...